In addition, in pancreatobiliary-type tumours, EGFR expression was found to be an adverse prognostic factor only in cases that received adjuvant gemcitabine, and a positive effect of gemcitabine was only seen in cases with low EGFR expression, with a significant interaction between EGFR expression and adjuvant gemcitabine in relation to overall survival. This evidence concerns the gene EGFR and neoplasm.